Inhibitor peptide corresponding to last 10 amino acids of the C-terminus of the GluA2 AMPA receptor subunit. Disrupts binding of GluA2 (at the C-terminal PDZ site) with glutamate receptor interacting protein (GRIP), AMPA receptor binding protein (ABP) and protein interacting with C kinase (PICK1). Increases amplitude of AMPA receptor-mediated currents and blocks long-term depression (LTD).
Control Peptide also available.
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 1 mg/ml in water|
Preparing Stock Solutions
The following data is based on the product molecular weight 1284.47. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||0.78 mL||3.89 mL||7.79 mL|
|5 mM||0.16 mL||0.78 mL||1.56 mL|
|10 mM||0.08 mL||0.39 mL||0.78 mL|
|50 mM||0.02 mL||0.08 mL||0.16 mL|
References are publications that support the biological activity of the product.
Collingridge and Isaac (2003) Functional roles of protein interactions with AMPA and kainate receptors. Neurosci.Res. 47 3 PMID: 12941441
Daw et al (2000) PDZ proteins interacting with C-terminal GluR2/3 are involved in a PKC-dependent regulation of AMPA receptors at hippocampal synapses. Neuron 28 873 PMID: 11163273
Kim et al (2001) Interaction of the AMPA receptor subunit GluR2/3 with PDZ domains regulates hippocampal long-term depression. Proc.Natl.Acad.Sci.U.S.A. 98 11725 PMID: 11573007
Li et al (1999) AMPA receptor-PDZ interactions in facilitation of spinal sensory synapses. Nat.Neurosci. 2 972 PMID: 10526335
If you know of a relevant reference for pep2-SVKI, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: pep2-SVKI, pep2-SVKI supplier, Peptide, inhibitors, inhibits, GluR2, subunit, binding, GRIP, ABP, PICK1, Increases, AMPA, current, amplitude, Glutamate, Receptors, iGlur, Ionotropic, GluA2, 1597, Tocris Bioscience
4 Citations for pep2-SVKI
Citations are publications that use Tocris products. Selected citations for pep2-SVKI include:
McElligott et al (2010) Distinct forms of Gq-receptor-dependent plasticity of excitatory transmission in the BNST are differentially affected by stress. J Neurosci 107 2271 PMID: 20133871
Xia et al (2007) Activity-dependent synaptic plasticity in retinal ganglion cells. J Neurosci 27 12221 PMID: 17989288
Grey and Burrell (2010) Co-induction of LTP and LTD and its regulation by protein kinases and phosphatases. J Neurophysiol 103 2737 PMID: 20457859
Dickinson et al (2009) A novel mechanism of hippocampal LTD involving muscarinic receptor-triggered interactions between AMPARs, GRIP and liprin-alpha. Mol Brain 2 18 PMID: 19534762
Do you know of a great paper that uses pep2-SVKI from Tocris? Please let us know.
Reviews for pep2-SVKI
There are currently no reviews for this product. Be the first to review pep2-SVKI and earn rewards!
Have you used pep2-SVKI?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.